Compare MT & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MT | ONC |
|---|---|---|
| Founded | 1976 | 2010 |
| Country | Luxembourg | Switzerland |
| Employees | N/A | 12000 |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.8B | 40.6B |
| IPO Year | 2003 | 2015 |
| Metric | MT | ONC |
|---|---|---|
| Price | $60.21 | $382.76 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 27 |
| Target Price | $77.80 | ★ $436.46 |
| AVG Volume (30 Days) | ★ 1.2M | 329.5K |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 0.80% | N/A |
| EPS Growth | N/A | ★ 140.43 |
| EPS | N/A | ★ 0.31 |
| Revenue | N/A | ★ $238,387,000.00 |
| Revenue This Year | $9.57 | $26.79 |
| Revenue Next Year | $9.30 | $14.91 |
| P/E Ratio | ★ $15.95 | $1,248.42 |
| Revenue Growth | N/A | ★ 22179.16 |
| 52 Week Low | $36.70 | $253.95 |
| 52 Week High | $79.68 | $388.66 |
| Indicator | MT | ONC |
|---|---|---|
| Relative Strength Index (RSI) | 31.52 | 63.34 |
| Support Level | $59.36 | $332.85 |
| Resistance Level | $64.18 | N/A |
| Average True Range (ATR) | 1.35 | 9.67 |
| MACD | 0.02 | 2.84 |
| Stochastic Oscillator | 5.07 | 87.76 |
ArcelorMittal SA is an integrated steel and mining company. The company's reportable operating segments include North America, Brazil, Europe, India and JVs, Sustainable Solutions, and Mining. It generates maximum revenue from the Europe segment. The Europe segment produces hot-rolled coil, cold-rolled coil, coated products, tinplate, plate, and slab. These products are sold to customers in the automotive, general, and packaging sectors, as well as producing long products consisting of sections, wire rods, rebar, billets, blooms and wire drawing, and tubular products. Geographically, it derives a majority of its revenue from the United States, followed by Brazil, Canada, Mexico, Argentina, and other markets.
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.